Nicotifloroside
CAS 17650-84-9
Nicotifloroside (CAS 17650-84-9) is a pharmaceutical compound with 7 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 40295.416666666664 nM | 24 | - |
| - | IC50 | 18.102666666666668 ug.mL-1 | 3 | - |
| - | Potency | 3827.7666666666664 nM | 3 | - |
| - | EC50 | 56500 nM | 2 | - |
| - | AC50 | 7779 nM | 1 | - |
| - | Ki | 32700 nM | 1 | - |
| - | MIC | 336400 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nicotifloroside used for in pharmaceutical contexts?
Nicotifloroside (CAS 17650-84-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nicotifloroside?
No adverse-event association or SIDER side-effect rows are rendered for Nicotifloroside in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nicotifloroside also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Nictoflorin with EU status "permitted".
What clinical phase is Nicotifloroside in?
No phase 1-4 clinical development badge is rendered for Nicotifloroside because the matched compound identifier rows do not contain a max-phase value.